4//SEC Filing
Sofinnova Venture Partners IX, L.P. 4
Accession 0000899243-19-027116
CIK 0001563577other
Filed
Nov 11, 7:00 PM ET
Accepted
Nov 12, 4:17 PM ET
Size
17.5 KB
Accession
0000899243-19-027116
Insider Transaction Report
Form 4
Mehra Anand
10% Owner
Transactions
- Conversion
Common Stock
2019-11-12+2,333,712→ 2,333,712 total - Conversion
Series C Preferred Stock
2019-11-12−2,709,659→ 0 total→ Common Stock (535,869 underlying) - Purchase
Common Stock
2019-11-12$12.00/sh+750,000$9,000,000→ 3,083,712 total - Conversion
Series B-2 Preferred Stock
2019-11-12−9,090,909→ 0 total→ Common Stock (1,797,843 underlying)
Sofinnova Venture Partners IX, L.P.
10% Owner
Transactions
- Conversion
Series B-2 Preferred Stock
2019-11-12−9,090,909→ 0 total→ Common Stock (1,797,843 underlying) - Conversion
Series C Preferred Stock
2019-11-12−2,709,659→ 0 total→ Common Stock (535,869 underlying) - Conversion
Common Stock
2019-11-12+2,333,712→ 2,333,712 total - Purchase
Common Stock
2019-11-12$12.00/sh+750,000$9,000,000→ 3,083,712 total
POWELL MICHAEL
Director10% Owner
Transactions
- Conversion
Series B-2 Preferred Stock
2019-11-12−9,090,909→ 0 total→ Common Stock (1,797,843 underlying) - Conversion
Series C Preferred Stock
2019-11-12−2,709,659→ 0 total→ Common Stock (535,869 underlying) - Conversion
Common Stock
2019-11-12+2,333,712→ 2,333,712 total - Purchase
Common Stock
2019-11-12$12.00/sh+750,000$9,000,000→ 3,083,712 total
HEALY JAMES
10% Owner
Transactions
- Conversion
Series B-2 Preferred Stock
2019-11-12−9,090,909→ 0 total→ Common Stock (1,797,843 underlying) - Conversion
Common Stock
2019-11-12+2,333,712→ 2,333,712 total - Conversion
Series C Preferred Stock
2019-11-12−2,709,659→ 0 total→ Common Stock (535,869 underlying) - Purchase
Common Stock
2019-11-12$12.00/sh+750,000$9,000,000→ 3,083,712 total
Sofinnova Management IX, L.L.C.
10% Owner
Transactions
- Conversion
Series B-2 Preferred Stock
2019-11-12−9,090,909→ 0 total→ Common Stock (1,797,843 underlying) - Conversion
Series C Preferred Stock
2019-11-12−2,709,659→ 0 total→ Common Stock (535,869 underlying) - Conversion
Common Stock
2019-11-12+2,333,712→ 2,333,712 total - Purchase
Common Stock
2019-11-12$12.00/sh+750,000$9,000,000→ 3,083,712 total
Footnotes (2)
- [F1]Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis.
- [F2]The shares reported herein are held of record by Sofinnova Venture Partners IX, L.P. ("SVP IX"). Dr. Michael F. Powell, Dr. James Healy and Dr. Anand Mehra are the managing members of Sofinnova Management IX, L.L.C., the general partner of SVP IX, and as such, may be deemed to share voting and investment power with respect to such shares. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of such reporting person's pecuniary interest therein.
Documents
Issuer
Galera Therapeutics, Inc.
CIK 0001563577
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001612133
Filing Metadata
- Form type
- 4
- Filed
- Nov 11, 7:00 PM ET
- Accepted
- Nov 12, 4:17 PM ET
- Size
- 17.5 KB